drugs acting on the kidney lectures 1 and 2

22
Drugs Acting on the Kidney (1 and 2) Professor John Peters E-mail [email protected]

Upload: pharmacology-education-project

Post on 16-Apr-2017

981 views

Category:

Education


0 download

TRANSCRIPT

Drugs Acting on the Kidney (1 and 2)

Professor John Peters

E-mail [email protected]

Learning Objectives

Following this lecture, students should be able to:

Recall the range of drugs that act upon the kidney

Identify the major sites of diuretic action in the nephron

Describe in detail the mechanism of action of the loop diuretics

List the clinical uses and main adverse effects of the loop diuretics

Describe in detail the mechanism of action of the thiazide diuretics

List the clinical uses and main adverse effects of the thiazide diuretics

Explain why loop and thiazide diuretics cause hypokalaemia

Describe the mechanisms of action of the potassium sparing diuretics

noting the distinct modes of action of aldosterone antagonists and

blockers of the epithelial sodium channel, ENaC

Describe the clinical uses of the potassium sparing diuretics and their

adverse effects

Recommended ReadingRang and Dale’s Pharmacology (7th. Ed.) Chapter 28

Drugs Acting on the Kidney

Drugs acting on the kidney include

Diuretics are the most commonly used agents that:

increase urine flow, normally by inhibiting the reabsorption of

electrolytes (mainly sodium salts) at various sites in the nephron

Diuretics

Vasopressin (antidiuretic hormone; ADH) receptor agonists and

antagonists

Uricosuric drugs (agents promoting excretion of uric acid into the

urine)

are used to enhance excretion of salt and water in conditions where

an increase in the volume of interstitial fluid (i.e. oedema) causes

tissue swelling

Inhibitors of sodium-glucose co-transporter 2 (SGLT2)

Those used in renal failure

Those that alter the pH of the urine

Formation of interstitial fluid is proportional to: (Pc – Pi) – (p - i)

Disease states that increase Pc or decrease p and produce

oedema include:

• the nephrotic syndrome

Oedema

results from an imbalance between the rate of formation and

absorption of interstitial fluid

Pc p

Pi i

Capillary

Interstitial fluid

• hepatic cirrhosis with ascites

• congestive heart failure

Diseases Associated With Oedema Responding to Diuretic Drug Therapy

The Nephrotic Syndrome

Involves a disorder of glomerular filtration, allowing protein

(largely albumin) to appear in the filtrate (proteinuria)

Decreased p

formation of

interstitial fluid

blood volume

cardiac outputOedema

Activation of the

RAAS

Na+ and H20

retentionPc,p

Congestive Heart Failure

Arises from reduced cardiac

output. Subsequent renal

hypoperfusion activates the renin-

angiotensin system

Expansion of blood volume

contributes to increased venous

and capillary pressures which,

combined with reduced p, causes

pulmonary and peripheral oedema

Hepatic Cirrhosis With Ascites

Increased pressure in the hepatic

portal vein, combined with decreased

production of albumin, causes loss of

fluid into the peritoneal cavity and

oedema (ascites)

Activation of the renin-angiotensin

system occurs in response to

decreased circulating volume

Oedema fluid mobilization by

diuretics. Note that collapse and

danger of thrombosis only occur

if massive use of diuretics is

employed). From Lüllmann et al.

(2000) Color Atlas of

Pharmacology

Sodium Reabsorption and the Major Sites of Diuretic Action in the Nephron

Proximal convoluted tubule1. Na+ (passive Cl- absorption)

2. Na+/H+ exchange (blocked by

carbonic anhydrase inhibitors)

Thick ascending limb of the loop of Henle3. Na+/K+/2Cl- co-transport (blocked

by loop diuretics)

Distal convoluted tubule

4. Na+/H+ exchange (blocked by

carbonic anhydrase inhibitors)

5. Na+/Cl- co-transport (blocked by

thiazide diuretics)

Collecting tubule

6. Na+/K+ exchange (blocked by

potassium-sparing diuretics)

1

2

3

4

5

6

Diuretics – General Aspects

A very large proportion of NaCl and H2O that passes into the filtrate

via the glomerulus is reabsorbed – hence even a small inhibition of

reuptake can cause a marked increase in Na+ excretion

The site of action of many diuretics (thiazides, loop agents, potassium

sparing) is the apical membrane of tubular cells hence, if hydrophilic,

they must enter the filtrate to access that site

Entry to the filtrate is by either:

glomerular filtration (for drug not bound to plasma protein)

secretion via transport process in the proximal tubule

two transport systems are important

The organic anion transporters (OATs) – transport acidic drugs (e.g.

thiazides and loop agents)

The organic cation transporters (OCTs) – transport basic drugs (e.g.

triamterene and amiloride)

Secretion results in the concentration of diuretic in the filtrate being higher

than that in blood, contributing to pharmacological selectivity

Secretion of Diuretics in the Proximal Tubule

Organic anion transporters (OATs)

At the basolateral membrane organic

anions (OA-) enter cell by either diffusion,

or in exchange for α-ketoglutarate (α-KG)

via OATs

α-KG is transported into cell (against a

concentration gradient) via a Na+-

dicarboxylate transporter

At the apical membrane, OA- enters the

lumen via either multidrug resistance

protein 2 (MRP2), or OAT4 (in exchange

for α-KG)

Organic cation transporters (OCTs)

At the basolateral membrane organic

cations (OC+) enter the cell either by

diffusion, or OCT, (both driven by

negative potential of cell interior and

against a concentration gradient)

At the apical membrane, OC+ enters the

lumen via either multidrug resistance

protein 1 (MRP1), or OC+/H+ antiporters

(OCTN)

Mechanism of Action of Loop Diuretics

Na+

Na+

Na+

K+K+

K+ K+

Cl-2Cl- Cl-

Zona occludens

+ve -ve4-10 mV

Lumen Interstitium

Mg2+

Ca2+

Mg2+Ca2+

Loop

diuretics

block Main

tain h

igh

ton

icity

of th

e med

ulla

Tubular epithelium

of the TALTriple transporter

(Na+/K+/2Cl- co-

transporter; NKCC2)

K+/Cl- co-transporter

Na+/K+ ATPase

Key

K channel (ROMK)

Cl channel

TAL = thick

ascending limb of

the loop of Henlé

Pharmacodynamics

Inhibit the Na+/K+/2Cl- carrier by binding to the Cl- site and thus:

Loop Diuretics (1)

Principal drugs: Furosemide and Bumetanide

Possess an additional, indirect, venodilator action (before diuresis)

that is beneficial in pulmonary oedema caused by heart failure–possibly results from: 1) increased formation of vasodilating

prostaglandins; 2) decreased responsiveness to angiotensin II and

noradrenaline; 3) opening of K+ channels in resistance vessels

Increase the load of Na+ delivered to distal regions of the nephron

(causing K+ loss)

Decrease the tonicity of the interstitium of the medulla

Prevent dilution of the filtrate in the thick ascending limb

Increase excretion of Ca2+ and Mg2+

Are ‘high ceiling’ agents causing 15-25% of filtered load of Na+ to

be excreted – rapid onset following i.v. administration

Loop Diuretics (2)

To treat hypertension (in patients resistant to other diuretics or anti-

hypertensive drugs - usually in the presence of renal insufficiency)

To reduce acutely elevated calcium levels in the serum

(hypercalcaemia) - note paracellular pathway in the thick

ascending limb of the loop of Henle

To increase urine volume in acute kidney failure

Clinical indications

To reduce salt and water overload associated with:

Acute pulmonary oedema (i.v.) Chronic heart failure

Chronic kidney failure Nephrotic syndrome

Hepatic cirrhosis with ascites

Pharmacokinetics

Well absorbed from the G.I. tract

Strongly bound to plasma protein

Enter nephron by the organic anion transport mechanism

Loop Diuretics (3)

Potassium loss producing low serum potassium levels

(hypokalaemia) – corrected by the concomitant use of potassium

sparing diuretics or potassium supplements

(note increases toxicity of digoxin and Class III antidysrhythmic drugs)

Increased plasma uric acid (hyperuricaemia) – partially

explained by competition between uric acid and loop agents

for the organic acid secretory mechanism in the proximal

tubule

Depletion of calcium and magnesium (paracellular pathway)

Decreased volume of circulating fluid (hypovolaemia) and

hypotension (particularly in the elderly)

Shift in acid-base towards alkaline side (metabolic alkalosis) –

caused by increased H+ secretion from intercalated cells in

collecting tubule

Adverse effects

Mechanism of Action of Thiazide Diuretics

Na+

Na+

Na++

K+

K+

Cl-Cl- Cl-

Zona occludens

Lumen Interstitium

Thiazide

diuretics

block

Tubular epithelium of the early distal

tubuleNa+/Cl- co-transporter

K+/Cl- co-transporter

Na+/K+ ATPase

Key

Cl- channel

K+ channel

K+K+

Pharmacodynamics

Inhibit the Na+/Cl- carrier by binding to the Cl- site and thus:

Cause up to 5% of Na+ to be excreted, producing a modest

diuresis

Possess an additional, indirect, vasodilator action (mechanism

uncertain) that contributes to their effectiveness in the treatment

of hypertension (where they are used in combination with other

antihypertensive agents)

Thiazide Diuretics (1)

Principal drugs: Bendroflumethiazide (bendrofluazide) and

hydrochlorothiazide

Prevent the dilution of filtrate in the early distal tubule

Increase the load of Na+ delivered to the collecting tubule (causing K+

loss)

Increase reabsorption of Ca2+ (cf. loop agents) (mechanism debatable)

Thiazide Diuretics (2)

Nephrogenic diabetes insipidus (caused by diminished

vasopressin responsiveness of the collecting ducts (paradoxically,

thiazides decrease the volume of urine – mechanism poorly

understood)

Renal stone disease (nephrolithiasis). Reduced urinary excretion

of Ca2+ discourages Ca2+ stone formation (mainly aggregates of

particles of calcium oxalate)

Severe resistant oedema (with a loop agent)

…and additionally in:

Clinical indications

Widely used in:

Mild heart failure Hypertension

Pharmacokinetics

Well absorbed from the G.I. tract

Enter nephron by the organic anion transport mechanism

(proximal tubule)

Thiazide Diuretics (3)

Adverse effects

Male sexual dysfunction

Hyperuricaemia – mechanism as for loop agents – may

precipitate gout

Metabolic alkalosis

Depletion of magnesium (not calcium)

Hypovolaemia and hypotension (particularly in the elderly)

Hypokalaemia, particularly likely and corrected as for loop

diuretics

Impaired glucose tolerance

Mechanism by which Loop and Thiazide Diuretics Cause Potassium Loss – Relevant Physiology

Aldosterone, a steroid hormone,

acts via cytoplasmic receptors to:

1. increase synthesis of the

Na+/K+ATPase

2. increase synthesis of a protein

that activates the epithelial Na+

channel (ENaC)

increase the number of H2O channels

(aquaporins) in the cell membrane

ADH (vasopressin), a peptide

hormone, acts via G-protein

coupled receptors to:

Na+ Na+

K+K+

Zona occludens

Lumen Interstitium

Late distal and collecting tubule

H2O

Cl- Cl-

H2O

Na+

K+

K+ Channels (ROMK), secrete K+

into the urine in the collecting

tubule

Note that K+ effectively exchanges

for reabsorbed Na+

Mechanism by which Loop and Thiazide Diuretics Cause Potassium Loss

Na+ Na+

K+K+

Zona occludens

Lumen Interstitium

Late distal and collecting tubule

H2O

Cl- Cl-

H2O

Na+

K+

1. Increased Na+ load caused by loop

or thiazide diuretic produces

enhanced reabsorption of Na+

2. Resulting charge separation

makes lumen more negative

and depolarizes the lumenal

vs. basolateral membrane-ve

3. Increased driving force on K+

across the lumenal membrane

leads to enhanced secretion of

K+. (Secretion of H+ is similarly

affected)

4. Secreted K+ (and H+) ‘washed

away’ by increased urinary

flow rate – development of

hypokalaemia (and metabolic

alkalosis)

Mechanism of Action of the Potassium Sparing Diuretics

Spironolactone and

Eplerenone

Compete with aldosterone for binding

to intracellular receptors causing:

1. decreased gene expression and

reduced synthesis of a protein

mediator that activates Na+

channels in the apical membrane

(site 1)

2. decreased numbers of

Na+/K+ATPase pumps in the

basolateral membrane (site 2)

Amiloride and Triamterene

Block the apical sodium channel

decrease Na reabsorption

Na+ Na+

K+K+

Zona occludens

Lumen Interstitium

Late distal and collecting tubule

H2O

Cl- Cl-

H2O

Na+

K+

X site 1site 2

Potassium Sparing Diuretics

Spironolactone and Eplerenone

Have limited diuretic action (modulated by aldosterone levels)

Competitively antagonise the action of aldosterone at

cytoplasmic aldosterone receptors, gain access to cytoplasm via

the basolateral membrane

Increase and decrease the excretion of Na+ and K+ respectively

Are well absorbed from the G.I. tract and in the case of

spironolactone rapidly metabolised to canrenone (which

accounts for most of the action of the drug)

Amiloride and Triamterene

Block lumenal sodium channels in the collecting tubules. Effect

on ion fluxes are similar to those of spironolactone

Enter the nephron via the organic cation transport system in the

proximal tubule

Triamterene is well absorbed from the G.I tract, absorption of

amiloride is poor

Clinical indications

The major use of potassium sparing diuretics is in conjunction

with other agents that cause potassium loss. Given alone, they

cause hyperkalaemia

Aldosterone antagonists are used in the treatment of:

Heart failure

Primary hyperaldosteronism (Conn’s syndrome)

Resistant essential hypertension

Secondary hyperaldosteronism (due to hepatic cirrhosis with

ascites)

Thiazide and loop diuretics activate the renin-angiotensin-

aldosterone system (in response to reduced blood pressure)

Aldosterone antagonists potentiate the actions of thiazide and

loop agents by blocking the effect of aldosterone